PRISMASOL BGK2/0
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- PRISMASOL BGK2/0
- Generic name
- MAGNESIUM CHLORIDE, DEXTROSE ANHYDROUS, LACTIC ACID, SODIUM CHLORIDE, SODIUM BICARBONATE, AND POTASSIUM CHLORIDE
- Manufacturer
- Vantive US Healthcare LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 7f675fee-8940-4ece-bb0c-75ac79d8708c
- SPL ID
- 3744e93f-f360-485a-bad4-948c168127c2
- Version
- 36
- Effective date
- 2025-05-31
- Source export date
- 2026-10-12
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/4760f38f2bcb10aa20ddbadb42b270d31e9f2a8024440d3af3dec8d11feb92ec/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 01:28:29
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 207026 | derived:openfda.application_number |
| application applno | NDA | 021703 | derived:openfda.application_number |
| application number | NDA021703 | openfda.application_number | |
| application number | NDA207026 | openfda.application_number | |
| brand name | PRISMASOL BK0/0/1.2 | openfda.brand_name | |
| brand name | PRISMASOL B22GK4/0 | openfda.brand_name | |
| brand name | PRISMASOL BGK4/0/1.2 | openfda.brand_name | |
| brand name | PRISMASOL BGK2/3.5 | openfda.brand_name | |
| brand name | PHOXILLUM BK4/2.5 | openfda.brand_name | |
| brand name | PRISMASOL BGK2/0 | openfda.brand_name | |
| brand name | PRISMASOL BGK0/2.5 | openfda.brand_name | |
| brand name | PRISMASOL BGK4/2.5 | openfda.brand_name | |
| brand name | PHOXILLUM B22K4/0 | openfda.brand_name | |
| generic name | MAGNESIUM CHLORIDE, LACTIC ACID, SODIUM CHLORIDE, AND SODIUM BICARBONATE | openfda.generic_name | |
| generic name | MAGNESIUM CHLORIDE, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE, AND SODIUM PHOSPHATE DIBASIC DIHYDRATE | openfda.generic_name | |
| generic name | CALCIUM CHLORIDE, MAGNESIUM CHLORIDE, DEXTROSE ANHYDROUS, LACTIC ACID, SODIUM CHLORIDE, AND SODIUM BICARBONATE | openfda.generic_name | |
| generic name | MAGNESIUM CHLORIDE, DEXTROSE ANHYDROUS, LACTIC ACID, SODIUM CHLORIDE, SODIUM BICARBONATE, AND POTASSIUM CHLORIDE | openfda.generic_name | |
| generic name | CALCIUM CHLORIDE, MAGNESIUM CHLORIDE, DEXTROSE ANHYDROUS, LACTIC ACID, SODIUM CHLORIDE, SODIUM BICARBONATE, AND POTASSIUM CHLORIDE | openfda.generic_name | |
| generic name | CALCIUM CHLORIDE, MAGNESIUM CHLORIDE, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE, AND SODIUM PHOSPHATE DIBASIC DIHYDRATE | openfda.generic_name | |
| manufacturer name | Vantive US Healthcare LLC | openfda.manufacturer_name | |
| ndc | package | 24571-108-06 | openfda.package_ndc |
| ndc | package | 24571-102-06 | openfda.package_ndc |
| ndc | package | 24571-113-06 | openfda.package_ndc |
| ndc | package | 24571-114-06 | openfda.package_ndc |
| ndc | package | 24571-117-06 | openfda.package_ndc |
| ndc | package | 24571-103-06 | openfda.package_ndc |
| ndc | package | 24571-116-06 | openfda.package_ndc |
| ndc | package | 24571-111-06 | openfda.package_ndc |
| ndc | package | 24571-105-06 | openfda.package_ndc |
| ndc | product | 24571-117 | openfda.product_ndc |
| ndc | product | 24571-116 | openfda.product_ndc |
| ndc | product | 24571-114 | openfda.product_ndc |
| ndc | product | 24571-111 | openfda.product_ndc |
| ndc | product | 24571-103 | openfda.product_ndc |
| ndc | product | 24571-113 | openfda.product_ndc |
| ndc | product | 24571-108 | openfda.product_ndc |
| ndc | product | 24571-102 | openfda.product_ndc |
| ndc | product | 24571-105 | openfda.product_ndc |
| ndc11 | package | 24571011306 | derived:openfda.package_ndc |
| ndc11 | package | 24571011706 | derived:openfda.package_ndc |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS • Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorus, other electrolytes and acid-base balance. Abnormalities may be corrected by the use of appropriate formulations and dosage of PRISMASOL and PHOXILLUM solutions ( 5.1 ) • Treatment may affect glucose levels. Monitor blood glucose levels. • Antidiabetic therapy adjustment or other corrective measures may be required during treatment ( 5.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Vantive US Healthcare LLC at 1855-857-0003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 5.1 Electrolyte and Volume Abnormalities PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately [ see Dosage and Administration (2) ]. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis . 5.2 Blood Glucose Abnormalities The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following adverse reactions have been identified during postapproval use with these or other similar products and therefore may occur with use of PHOXILLUM or PRISMASOL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. • Metabolic acidosis • Hypotension • Acid-base disorders • Electrolyte imbalance including calcium ionized increased (reported in PRISMASOL solutions containing calcium), hyperphosphatemia, and hypophosphatemia • Fluid imbalance
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.